Oxycodone Purification via Preliminary Hydrogenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for producing oxycodone hydrochloride result in high levels of 14-hydroxycodeinone, which are above the desired limits set by recent ICH guidelines and pose gene-toxin risks due to their potential for Michael addition reactions with biological nucleophiles like cysteine, necessitating effective reduction methods.
Innovation Solution
The process involves generating oxycodone base from thebaine using peracetic acid in aqueous acetic acid followed by palladium-catalyzed hydrogenation, then converting it to the hydrochloride salt in an alcohol solvent, where residual 14-hydroxycodeinone is reduced using zinc or magnesium metal or thiol compounds like sodium hydrosulfite, achieving levels below 5 ppm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional oxidation and hydrogenation methods are used to produce oxycodone from thebaine, then production efficiency is maintained, but 14-hydroxycodeinone levels remain high (above ICH guidelines)
Solution Approach 1:
The patent applies preliminary action by conducting a first hydrogenation step immediately after oxidation to convert 14-hydroxycodeinone to 14-hydroxycodeine before the main oxycodone formation step. This preliminary reduction prevents the accumulation of the unwanted intermediate, allowing subsequent steps to proceed efficiently without requiring extensive downstream purification, thus maintaining productivity while achieving precise impurity control
Solution Approach 2:
The patent uses 14-hydroxycodeine as an intermediary substance. Instead of directly converting thebaine to oxycodone, the process introduces 14-hydroxycodeine as a stable intermediate that can be easily separated or further converted. This intermediary approach allows for better control of the reaction pathway and enables the removal of problematic 14-hydroxycodeinone without compromising overall production efficiency
2Manufacturing precision
If extensive purification steps are added to reduce 14-hydroxycodeinone levels, then impurity levels decrease, but process complexity and cost increase
Solution Approach 1:
By performing the first hydrogenation step to convert 14-hydroxycodeinone to 14-hydroxycodeine before the main reaction sequence, the patent eliminates the need for extensive downstream purification steps. This preliminary action addresses the impurity issue at the source, maintaining manufacturing precision while avoiding the addition of complex purification equipment and procedures
Solution Approach 2:
The patent changes the reaction parameters by introducing a controlled hydrogenation step with specific catalysts and conditions that selectively convert 14-hydroxycodeinone without affecting the main oxycodone synthesis pathway. This parameter change allows for in-process purification, reducing the need for additional complex separation steps while achieving the required impurity levels
3Object-affected harmful factors
If 14-hydroxycodeinone levels are not reduced, then production cost and time are lower, but gene-toxin risks increase due to Michael addition reactions
Solution Approach 1:
The patent applies preliminary action by conducting a first hydrogenation step immediately after oxidation to convert 14-hydroxycodeinone to 14-hydroxycodeine before the main oxycodone formation step. This preliminary reduction eliminates the gene-toxin risk by removing the reactive α,β-unsaturated ketone functionality while maintaining production efficiency through integrated process design that avoids separate purification steps
Solution Approach 2:
The patent converts the potentially harmful 14-hydroxycodeinone into beneficial 14-hydroxycodeine through controlled hydrogenation. The reactive impurity is transformed into a stable intermediate that can be easily managed or converted further, turning a harmful factor into a useful component of the process while eliminating gene-toxin risks without sacrificing productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces 14-hydroxycodeinone levels in oxycodone hydrochloride to less than 5 ppm, addressing the gene-toxin concerns and meeting stringent ICH guidelines while maintaining industrially acceptable yields.
Implementation Method 1
catalytic hydrogenation using a noble metal catalyst, preferably palladium, and hydrogen gas
Implementation Method 2
The most common method for the conversion of 14-hydroxycodeinone to oxycodone is catalytic hydrogenation
Implementation Method 3
residual 14-hydroxycodeinone is reduced using zinc or magnesium metal
Implementation Method 4
thiol compounds like sodium hydrosulfite
Data Source
AI summary
The present invention is directed to processes for preparing oxycodone base having less than 10 ppm of 14-hydroxycodeinone, oxycodone hydrochloride having less than 50 ppm of 14-hydroxycodeinone, and oxycodone hydrochloride having less than 75 ppm of 14-hydroxycodeinone.